Pathophysiologically, BRAF-inhibitors can bind to and activate wild-type RAF leading to “paradoxical” MAPK-pathway activation in BRAFV600 wild-type skin cells, which manifests clinically as skin neoplasms [11]. The gene discussed is BRAF; the disease is skin neoplasm.